866-997-4948(US-Canada Toll Free)

Gauchers Disease - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Diseases & Conditions

No. of Pages : 86 Pages


Global Markets Directs, Gaucher's Disease Pipeline Review, H1 2015, provides an overview of the Gaucher's Diseases therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gaucher's Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gaucher's Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gaucher's Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
B-Cell Chronic Lymphocytic Leukemia Overview 9
Therapeutics Development 10
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 10
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 11
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 12
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 14
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 18
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 20
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
Amgen Inc. 22
BioNovion B.V. 23
Celgene Corporation 24
Dynavax Technologies Corporation 25
Eisai Co., Ltd. 26
F. Hoffmann-La Roche Ltd. 27
iDD biotech SAS 28
Immunomedics, Inc. 29
Juno Therapeutics Inc. 30
MABLife S.A.S 31
Nippon Shinyaku Co., Ltd. 32
Noxxon Pharma AG 33
Ono Pharmaceutical Co., Ltd. 34
Regeneron Pharmaceuticals, Inc. 35
SBI Biotech Co., Ltd. 36
TheraMAB LLC. 37
Vivia Biotech, S.L. 38
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
202-b - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
alemtuzumab biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AMG-319 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bafetinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BION-1301 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Cell Therapy for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cell Therapy for Hematological Malignancies - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cell Therapy to Target CD16 for CLL and NHL - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cell Therapy to Target CD19 for Cancer - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Cell Therapy to Target CD19 for Oncology - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
E-7449 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GNKS-356 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IDD-001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IDD-002 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ilorasertib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
lenalidomide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MAT-304 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
olaptesed pegol - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ONO-4059 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
REGN-1979 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SD-101 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules for Oncology - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TAB-08 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
tocilizumab - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Vivia-009 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 92
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 107
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 108
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 109
Featured News & Press Releases 109
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 109
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 110

Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Table


Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2015 10
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H1 2015 21
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H1 2015 22
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H1 2015 23
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H1 2015 24
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H1 2015 25
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H1 2015 26
B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 27
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2015 28
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H1 2015 29
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H1 2015 30
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MABLife S.A.S, H1 2015 31
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 32
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2015 33
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 34
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 35
B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H1 2015 36
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC., H1 2015 37
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2015 92
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2015 107
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2015 108

List of Chart


Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2015 10
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Top 10 Targets, H1 2015 40
Number of Products by Stage and Top 10 Targets, H1 2015 40
Number of Products by Top 10 Mechanism of Actions, H1 2015 42
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42
Number of Products by Top 10 Routes of Administration, H1 2015 44
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44
Number of Products by Top 10 Molecule Types, H1 2015 46
Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *